HOME >> MEDICINE >> NEWS
GlaxoSmithKline's Havrix now approved for use in children aged 12 months and older

Philadelphia, PA October 18, 2005 GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) approved the expanded use of Havrix(R) (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix and may help to further reduce the incidence of hepatitis A in the United States, particularly among young children who often transmit the disease.

"The expanded indication of Havrix marks an important milestone in the fight against hepatitis A in the United States," said William P. Hitchcock, M.D., of the American Board of Pediatrics, La Jolla, California. "Immunizing children under age two helps protect a very vulnerable population that often does not show symptoms of the disease but frequently spreads it to other children and family members."

Havrix for the Prevention of Hepatitis A in Children Aged 12 Months and Older
The FDA approved the expanded use of Havrix in children to 12 months and older on the basis of a pivotal trial which studied the administration of Havrix in children in the United States and Australia. The prospective, open, comparative, multi-center clinical trial involved over 1,000 healthy children and showed Havrix given to children down to the age of 11 months to be comparable to Havrix given to children approximately two years of age with regard to safety and immunogenicity. The study also showed that Havrix can be given concomitantly with OMNIHIBTM [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)], also called Hib conjugate vaccine (PRP-T).

Each subject was enrolled in one of five groups according to their age and previous vaccination history and vaccinated with either Havrix alone or Havrix with Infanrix (D
'"/>


18-Oct-2005


Page: 1 2 3

Related medicine news :

1. Did drug reps encourage doctors to prescribe gabapentin for nonapproved uses?
2. NIH scientists honored for FDA-approved cervical cancer vaccine breakthrough
3. Previously approved drugs may be helpful in fatal pediatric disorder
4. Shires DAYTRANA(TM) transdermal patch approved by FDA for treatment of ADHD
5. Higher dose formulation of FOSRENOL approved to reduce serum phosphorus in esrd patients
6. FDA approved ROZEREM (ramelteon)
7. Cedars-Sinais live donor liver transplant program receives unos-approved designation
8. Many drugs prescribed for chronic insomnia are not approved for that purpose
9. Sildenafil (Viagra) approved for treatment of pulmonary arterial hypertension (PAH) as Revatio
10. Chinese children with hearing devices benefit from new speech test
11. Seat belt injuries could signal more serious trauma in children

Post Your Comments:
(Date:2/27/2015)... Mequon, Wisconsin (PRWEB) February 27, 2015 ... facial plastic surgeons , is pleased to announce the ... location now open in Delafield. Quintessa has begun seeing ... Campbell, the new Delafield location will offer a variety ... patients, including: Botox, filler injectables, micro laser peels, chemical ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Legislation ... Committee, includes a pharmacy provision to help prevent ... the pharmacy counter. The Protecting the Integrity of ... Health Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... address the prescription drug abuse epidemic and implement ...
(Date:2/27/2015)... The winter season is here, and with ... mold grows, it can be harmful to the home and ... consequences of mold growth with the help of Enviro-Test. Enviro-Test, ... on the best ways to prevent mold during the winter ... conditions for mold to thrive. Mold must be removed properly, ...
(Date:2/27/2015)... FACE Skincare~Medical~Wellness, a multiaward-winning leader in ... combination to take fifteen years off of an ... new treatment introduced that is the first and ... improve lines and wrinkles on the Décolleté. This ... from the stubborn vertical lines between the upper ...
(Date:2/27/2015)... February 27, 2015 The UC Davis ... expertise have made it a beacon of hope for ... has been acknowledged by the national society committed to ... Huntington’s Disease Society of America — as a Level ... acknowledgement recognizes the center’s service to over 300 families ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Face Skincare Announces New Combination Therapy 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
(Date:2/27/2015)... 27, 2015  Boston Scientific Corporation (NYSE: ... 2015 Annual Healthcare Conference on March 10 in ... Brennan , executive vice president and chief financial officer, ... will participate in a 25-minute question and answer session ... 1:05 p.m. ET. Following a 5-minute break, a question ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
Cached News: